← Back to Search

MySmartSkin Renewal for Melanoma

N/A

Recruiting

Led By Sharon Manne, MD

Research Sponsored by Rutgers, The State University of New Jersey

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Diagnosis of primary pathologic stage 0-III cutaneous malignant melanoma

≥ 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 18 months

Awards & highlights

Study Summary

This trial is testing an intervention to improve microsatellite stable (MSS) in order to assess its effects on outcomes including clinical outcomes and identifying barriers and facilitators to its future use.

Who is the study for?

This trial is for adults over 18 who've had stage 0-III melanoma, are three months to five years post-surgery without current cancer evidence. Participants should have missed at least one full-body skin self-exam in the past three months and must have internet access and understand English.Check my eligibility

What is being tested?

The study tests an enhanced MySmartSkin (MSS) service with stakeholder feedback aimed at improving its reach and effectiveness. It includes an educational webpage on skin self-exams (SSE) and evaluates how well these tools help find new melanomas.See study design

What are the potential side effects?

Since this trial focuses on a non-invasive web-based intervention, traditional physical side effects are not expected. However, participants may experience stress or anxiety from increased attention to their health status.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My skin cancer is at an early to mid-stage.

Select...

I am 18 years old or older.

Select...

I currently show no signs of cancer.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 18 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~18 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 18 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Body part

Secondary outcome measures

Melanoma Diagnosis

Melanoma Diagnosis Date

Melanoma

Other outcome measures

Age

Average UV Index

Date of Diagnosis

+14 more

Trial Design

3Treatment groups

Experimental Treatment

Active Control

Group I: Involves the longitudinal RCT comparing behavioral outcomes and effectiveness (Mo.16 -60)Experimental Treatment1 Intervention

RCT of enhanced MSS testing effectiveness (thorough SSE, sun protection behavior Involves the longitudinal RCT comparing behavioral outcomes and effectiveness of enhanced MSS versus an educational webpage on SSE as well as new recurrences/melanomas

Group II: Enhance MSS using multi-level stakeholder collaboration (Mo.1-15)Experimental Treatment1 Intervention

Enhancements of MSS to increase intervention effects - theory - based strategies (PHM), (BCT)

Group III: Aim 3: Assess implementation outcomes, identify factors relevant for future scale-up (Mo.17-60)Active Control1 Intervention

Assessment of implementation outcomes and key contextual factors from the perspective of multi - level stakeholders

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH

13,662 Previous Clinical Trials

40,925,688 Total Patients Enrolled

557 Trials studying Melanoma

192,804 Patients Enrolled for Melanoma

Rutgers, The State University of New JerseyLead Sponsor

429 Previous Clinical Trials

63,847 Total Patients Enrolled

11 Trials studying Melanoma

1,903 Patients Enrolled for Melanoma

Sharon Manne, MDPrincipal InvestigatorRutgers Cancer Institute of New Jersey

Media Library

MSS enhancement Clinical Trial Eligibility Overview. Trial Name: NCT05373823 — N/A

Melanoma Research Study Groups: Enhance MSS using multi-level stakeholder collaboration (Mo.1-15), Involves the longitudinal RCT comparing behavioral outcomes and effectiveness (Mo.16 -60), Aim 3: Assess implementation outcomes, identify factors relevant for future scale-up (Mo.17-60)

Melanoma Clinical Trial 2023: MSS enhancement Highlights & Side Effects. Trial Name: NCT05373823 — N/A

MSS enhancement 2023 Treatment Timeline for Medical Study. Trial Name: NCT05373823 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this research currently in the process of enrolling participants?

"According to the data posted on clinicaltrials.gov, this research endeavour is no longer inviting applicants; it was initially advertised in January of 2023 and last edited October 17th 2022. Nonetheless, other medical trials are currently requesting participants - 755 such experiments exist as of now."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

MySmartSkin Online Skin Self-exam Intervention for Melanoma Survivors

Sharon Manne, PhD 2023. "MySmartSkin Online Skin Self-exam Intervention for Melanoma Survivors". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05373823.